


CORRECTION

Open Access



# Correction to: Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity

Maria Laura Saiz<sup>1†</sup>, Marta L. DeDiego<sup>2†</sup>, Darío López-García<sup>2</sup>, Viviana Corte-Iglesias<sup>1</sup>, Aroa Baragaño-Raneros<sup>1</sup>, Ivan Astola<sup>3,4</sup>, Victor Asensi<sup>5</sup>, Carlos López-Larrea<sup>1,6\*</sup> and Beatriz Suarez-Alvarez<sup>1</sup> 

## Correction to: *Clin Epigenet* (2021) 13:187

<https://doi.org/10.1186/s13148-021-01168-5>

Following publication of the original article [1], the authors identified errors in Fig. 7 and in the co-author name. Panels A and B of Fig. 7 were the same as panels C and D. At the last name of Marta L. De Diego the space

between “De” and “Diego” must be removed. The correct name is “Marta L. DeDiego”. These have been corrected with this erratum.

The corrected Fig. 7 is given below:

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1186/s13148-021-01168-5>.

\*Correspondence: [inmuno@hca.es](mailto:inmuno@hca.es)


†Maria Laura Saiz and Marta L. DeDiego have contributed equally to this work

<sup>1</sup> Translational Immunology Laboratory, Health Research Institute of Asturias (ISPA), Oviedo, Spain

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



**Fig. 7** Treatment with VPA inhibits the inflammatory response triggered by TNF-α induction and SARS-CoV-2 infection. **a, b** HK-2 and Huh-7 cells were treated with VPA (4, 8, and 16 mM) for 24 h and (10 ng/ml) was added in the final 3 h. **c, d** HK-2 and Huh-7 cells were cultured with TNF-α (10 ng/ml) for 3 h and without removing the culture medium, and VPA (4, 8, and 16 mM) was added for an additional 24 h. TNF-α and IL-6 expression was quantified by RT-qPCR and represented as n-fold induction over the levels of mock-treated cells. **e** Huh-7 cells were treated with VPA (4, 8, and 16 mM) for 24 h before SARS-CoV-2 infection (MOI 0.5), and TNF-α and IL-6 expression was evaluated by RT-qPCR at 24 and/or 48 hpi and represented as the n-fold induction over the levels of mock-infected cells. **f** Huh-7 cells were infected with SARS-CoV-2 and 1 hpi, cells were left untreated (control) or treated with 4, 8, and 16 mM of VPA for 24 h. TNF-α expression was analyzed by RT-qPCR and represented as the n-fold induction over the levels of mock-infected cells. All samples were normalized relative to GAPDH expression using the 2<sup>-ΔCT</sup> method. Data are represented as the mean ± SD of at least three independent experiments. \*p < 0.05

**Author details**

<sup>1</sup>Translational Immunology Laboratory, Health Research Institute of Asturias (ISPA), Oviedo, Spain. <sup>2</sup>Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain. <sup>3</sup>Intensive Care Department, Hospital Universitario Central de Asturias, Oviedo, Spain. <sup>4</sup>Translational Microbiology Research Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain. <sup>5</sup>Infectious Diseases Unit, Translational Research in Infectious Diseases Group, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain. <sup>6</sup>Department of Immunology, Hospital Universitario Central De Asturias, Oviedo, Spain.

**Reference**

1. Saiz ML, et al. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity. *Clin Epigenet.* 2021. <https://doi.org/10.1186/s13148-021-01168-5>.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.